Recent Company News

• 09:43 PM ET Aug 21, 2026
  

  CSPC Pharmaceutical Group upgraded to buy at UOB Kay Hian Securities (HK$9.19, 0.00)

• 06:02 AM ET Aug 21, 2026
  

  Street Takeaways - CSPC Pharmaceutical Group H1 earnings (HK$9.19, 0.00)

• 12:46 AM ET Aug 20, 2026
  

  StreetAccount Metrics Recap - CSPC Pharmaceutical Group H1 Earnings (HK$9.86, +1.17)

• 12:25 AM ET Aug 20, 2026
  

  CSPC Pharmaceutical Group reports H1 underlying net income attributable CNY6.16B, +166% vs year-ago CNY2.32B (HK$9.86, +1.17)

• 11:11 PM ET Aug 19, 2026
  

  StreetAccount Summary - Trading higher/lower: Asia mid-morning

• 11:04 PM ET Aug 12, 2026
  

  StreetAccount Summary - Trading higher/lower: Hong Kong mid-morning

• 07:39 AM ET Aug 19, 2026
  

  CSPC Pharmaceutical initiates phase Ib/II trial of SYS6090 for hepatocellular carcinoma (HK$8.69, 0.00)

• 08:41 PM ET Aug 18, 2026
  

  CSPC Pharmaceutical Group initiated buy at Guosheng Securities (HK$8.80, 0.00)

• 06:06 AM ET Aug 18, 2026
  

  NMPA accepts for priority review NDA for CSPC Pharmaceutical and Alphamab Oncology's KN026 combined with HB1801 for HER2-positive breast cancer (HK$8.80, 0.00)